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Abstract Candida species belong to the normal microbiota
of the oral cavity and gastrointestinal and vaginal tracts, and
are responsible for several clinical manifestations, from mu-
cocutaneous overgrowth to bloodstream infections. Once be-
lieved to be non-pathogenic, Candida glabrata was rapidly
blamable for many human diseases. Year after year, these
pathological circumstances are more recurrent and problemat-
ic to treat, especially when patients reveal any level of immu-
nosuppression. These difficulties arise from the capacity of C.
glabrata to form biofilms and also from its high resistance to
traditional antifungal therapies. Thus, this review intends to
present an excerpt of the biology, epidemiology, and patholo-
gy of C. glabrata , and detail an approach to its resistance
mechanisms based on studies carried out up to the present.
Introduction
The incidence of fungal infections has increased significantly
in the last several decades, contributing to high levels of
morbidity and mortality [1]. This fact is mainly due to the rise
in antimicrobial resistance and the limited number of efficient
antifungal drugs, which still have many side effects. Of the
fungi considered as human pathogens, some members of the
genusCandida are the most commonly recovered from fungal
infections [2]. The use of broad-spectrum antibiotics, catheters
and parenteral nutrition, the presence of immunosuppression,
the disruption of mucosal barriers, and the use of chemother-
apy and radiotherapy are among the most significant predis-
posing factors for invasive fungal infections development [3].
The Candida genus comprises over 150 heterogeneous
species [4], but only a minority are associated to human
candidosis, since roughly 65% ofCandida species are unable
to grow at a temperature of 37 °C, enabling them to prosper as
pathogens or commensals of humans [4]. The genus is com-
posed of a heterogeneous group of organisms, and more than
17 different Candida species are known to be etiological
agents of human infections; however, more than 90 % of
invasive infections are due to Candida species [5]. The path-
ogenicity of Candida species is attributed to certain virulence
factors, such as the ability to evade host defenses, adhesion
and biofilm formation (on host tissue or on medical devices),
and the production of tissue-damaging hydrolytic enzymes
such as proteases, phospholipases, and hemolysins [2].
Of the Candida species isolated from humans, Candida
albicans is the most prevalent in both health and disease condi-
tions. However, whilstmycological studies have been shown that
C. albicans represents over 80 % of isolates, in the last two
decades, the number of infections due to non-Candida albicans
Candida (NCAC) species has increased significantly, namely
due to Candida glabrata . In fact, recent studies suggested that
fungemia has been associated with NCAC species [6–9] and the
incidence of C. glabrata is higher in adults than in children, and
is lower in neonates [10, 11]. This species lacks a number of the
virulence factors allied to other Candida pathogenicity, such as
hyphal growth or the ability to secrete proteases [12]. Despite
that, C. glabrata is a growing concern in clinical settings, where
it causes mucosal infections and is related to around 15 % of all
Candida-related systemic bloodstream infections [13–19].
Candida epidemiology has shown that humans are ex-
posed recurrently to Candida in food and other sources.
Vazquez and colleagues [20] revealed that patients with a
new acquisition of C. glabrata had extended hospitalization
and repeated prior antimicrobial use compared to patients with
no Candida exposition. Moreover, differently from C.
albicans , former studies [21, 22] indicated that 75 % of
patients generally carried the same strain type of C. glabrata
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over time [20], withminimal strain diversity among individual
patients.
Candida infection is the third most common cause of nos-
ocomial infections in patients requiring intensive care and the
most common etiologic agent of fungal-related biofilm infec-
tions. Biofilms are biological communities with an extraordi-
nary degree of organization, in which micro-organisms form
structured, coordinated, and functional communities, embedded
in a self-created extracellular matrix. Biofilm production is also
associated with a high level of antimicrobial resistance of the
associated organisms. The ability of Candida species to form
drug-resistant biofilms is an important factor in their contribu-
tion to human disease, but it is also recognized that the more
general provision of new medical practices (immunosuppres-
sive therapy, invasive surgical procedures, and the use of broad-
spectrum antibiotics) are highly significant as well [23–25]. In
the widely held view of microbial biofilms [26], sessile cells
within biofilms are less susceptible to antimicrobial agents than
planktonic cells [27], since the development of drug resistance
has been linked with an increase in the maturation process.
Antifungal drugs are active by either killing the fungal cells,
e.g., affecting a substance in the cell wall, causing a leak out of
the cell contents and death, or by preventing fungal cells from
growing and reproducing. There are many antifungal classes:
polyenes, which includes amphotericin, nystatin, and pimaricin;
azoles, including fluconazole, itraconazole, ketoconazole,micon-
azole, voriconazole, posaconazole, and rosaconazole;
echinocandins, such as caspofungin and micafungin; and
allylamines, including naftifine, terbinafine, morpholine drug,
amorolfine, and griseofulvin; and the antimetabolite antifungal
drugs, in which 5-fluorocytosine is incorporated.
Amphotericin B and fluconazole are among the antifungal
agents most widely used to treat systemic fungal infections.
The former has its use limited due to its high degree of toxicity
in humans. The latter is frequently prescribed to treatCandida
infections due to its excellent patient tolerance and minimal
side effects, although a great number of species of Candida
display fluconazole resistance. The growing worldwide use of
this drug to treat candidemia is one of the principal causes of
the recent increase in the prevalence of NCAC species [28].
Concerning that information and despite significant research
aimed at identifying virulence factors ofC. glabrata [2, 4, 15],
little is known about the mechanism of its resistance to anti-
fungal agents. Thus, in this review, we aim to provide an
overview of the C. glabrata resistance factors, as well as the
biology and virulence factors of C. glabrata .
Physiological and biochemical characterization
of Candida glabrata
Originally, C. glabrata was classified in the Torulopsis genus
due to its lack of pseudohyphae. In fact, in 1978, this species
was shown to have no polymorphic growing, being only
grown as blastoconidia. It was then considered that the ability
to form pseudohyphae was not a trustworthy distinctive aspect
for members of the genus Candida and it was suggested that
Torulopsis glabrata might be classified in the genusCandida ,
for its human pathogenicity [29]. On Sabouraud Dextrose
Agar (SDA), C. glabrata forms shining, smooth, and cream-
colored colonies, which are fairly indistinguishable from those
of other Candida species, except for their relative size, which
can be rather small. Candida glabrata cells (1–4 μm) are
remarkably smaller than C. albicans (4–6 μm), Candida
tropicalis (4–8 μm), and Candida parapsilosis (2.5-4 μm)
blastoconidia [4]. Regarding the chromogenic medium,
CHROMagar™ Candida (CHROMagar, Paris, France), C.
glabrata colonies appear white, pink to purple, and
concerning the biochemical reactions, it ferments and assim-
ilates only glucose and trehalose. Finally, in relation to its
genetic features, C. glabrata has a critical distinction due to
its haploid genome, in contrast to the diploid genome of C.
albicans and several other NCAC species [29]. A summarized
list of features is presented on Table 1.
The genome of C. glabrata (CBS138/American Type Cul-
ture Collection, ATCC2001) was sequenced [29, 30], showing
that this species shares a common ancestor with Saccharomy-
ces cerevisiae [31]. Thus, the first has lost many more genes
than S. cerevisiae , decreasing traces of duplication to a min-
imum and leading to the complete loss of some metabolic
pathways [29, 30]. Even though it has reserved homology
with the S. cerevisiae genes of the mating pathway [32], C.
glabrata is haploid and, indeed, several deficiencies in the
mating pathway have been also identified [33, 34].
Moreover C. glabrata has lost various genes, such as the
gene needed for galactose (GAL1 , GAL7 , GAL10), phosphate
(PHO3 , PHO5 , PHO11 , PHO12), nitrogen (DAL1 , DAL2),
sulfur metabolism (SAM4 ), and pyridoxine biosynthesis
(SNO1 , SNO2 , SNO3) [12, 35]. The natural auxotrophy of C.
glabrata , such as the inability to synthesize nicotinic acid,
pyridoxine, and thiamine [7], and the inability to use galactose
or engineered amino acid auxotrophy [35, 36], is generally
compensated by the mammalian host environment. Additional-
ly, expansion of genes involved in cell wall organization oc-
curred in C. glabrata , possibly facilitating adherence to a broad
spectrum of surfaces. It is important to emphasize that the gain
and loss of these relevant genes may be crucial for a functional
differentiation between species and could be related to C.
glabrata’s adaptation as a mammalian commensal [12, 33–36].
Nutrient limitation, oxidative response, competition with
other microorganisms, causative agents as protective mecha-
nisms, and the impossibility to generate resistant spores are
stress causes (intrinsic or habitat sourced) to C. glabrata [37].
Hence, somatic cells require holding viability on surfaces
outside the host, demanding a high stress tolerance. Matched
to otherCandida species,C. glabrata appears to be one of the
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more robust, being able to survive on inanimate surfaces for
more than 5 months, while the viability of C. albicans is
limited to 4 months and C. parapsilosis cells die after 2 weeks
[37, 38].
Candida glabrata–host interactions
Candida glabrata cells are able to colonize commensally the
mouth, esophagus, intestines, and vagina mucosal surfaces,
but very little is known about its interaction with the host and
defense mechanisms. It is expected that host mechanisms
control C. glabrata , suppressing the expression of its patho-
genic properties, and, in this manner, preventing infection [37,
38].
Phagocytic cells (neutrophils, dendritic cells, and macro-
phages) constitute the primary response of the innate host
immune system against Candida infections. After internaliza-
tion of the fungal pathogen, formation of the phagolysosome
continues inside the phagocytic cells, for the destruction of the
overwhelmed microorganism. The organelle harbors a dam-
aging and highly toxic internal phagolysosome for the elimi-
nation, including low pH, hydrolytic enzymes, potent reactive
oxygen and nitrogen species (DNA damage), proteins, and
lipids of the pathogen. Trapped microorganisms have devel-
oped diverse strategies to survive the oxidative burst and to
escape from the phagolysosome, including many antioxidant
defense enzymes (catalase, reductase, superoxide dismutase,
thioredoxin- and glutathione-dependent peroxidases) [38–40].
Candida albicans and C. glabrata carry only one catalase
gene (CTA1) [41, 42]. Since both stress and non-fermentable
carbon source can induce the expression of CTA1 , its regula-
tion is a combination between two catalase genes which can
be found in S. cerevisiae [43]. Though not yet unswervingly
shown, the complex regulation and conservation of this en-
zyme in C. glabrata suggests a role in peroxide stress resis-
tance in the host environment. In yeasts, a great majority of the
almost 500 stress genes are under the control of four transcrip-
tion factors: ScYap1 (the central component of the oxidative
stress response regulated by H2O2 or diamine), ScSkn7 (im-
portant for peroxide stress protection and for the induction of
TRX2 , TRR1 , TSA1 , and CTA1 [44]), and ScMsn2/ScMsn4
[45, 46]. The core response to oxidative stress consists of
thioredoxin cofactor Trx2, glutathione peroxidase Gpx2, and
catalase Cta1, thioredoxin peroxidases (Tsa1 and Tsa2), and
thioredoxin reductases (Trr1 and Trr2). Finally, the transcrip-
tion of the C. glabrata copper–zinc superoxide dismutase
(SOD) genes, SOD1 and SOD2 , is regulated in another way
from yeast. Both SOD genes are induced by carbon source
depletion, whereas, significantly, SOD1 is expressed consti-
tutively [47].
Surrounded fungal pathogens control their metabolism in
the glucose-deficient environment inside the macrophage and
adjust their expression profile towards genes involved in the
employment of alternative carbon sources. Genes of the gly-
colytic pathway are repressed, whereas genes encoding for
Table 1 Characterization of
Candida glabrata general fea-
tures [12, 29, 30]
Feature Candida glabrata characteristics
Ploidy Haploid
Hyphae/pseudohyphae Absent
Colonies on SDA Very small/cream-color
Cell size 1-4 μm
Growth on CHROMagar™ White, pink/purple
Biochemical reactions Ferments and assimilates glucose
and trehalose
Virulence Opportunistic pathogen
Major sites of infection Vaginal, oral, disseminated
Biofilm formation Yes
Major adhesins Lectins
Mating genes Present
Sexual cycle Unknown
Clonal population structure Yes
Phenotypic switching Present
Auxotrophy Niacin, thiamine, pyridoxine
Mitochondrial function Petite-positive
Epidemiology of infection Principally nosocomial (except vaginal) (frequently mixed fungal infection)
Immunocompromised or debilitated host
Specific risk factors: prolonged hospitalization, prior antibiotic use,
use of fluconazole, patient exposure, hand carriage by hospital personnel
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proteins are needed for gluconeogenesis, β-oxidation,
glyoxylate cycle, autophagy, peroxisome proliferation, and
amino and acetate transports are induced [48, 49]. Glucose
sensing involves two antagonizing mechanisms, depending on
the glucose availability or glucose limitation. Snf1, a protein
kinase, which stimulates the transcription of glucose-repressed
genes, plays a central role during glucose starvation in S.
cerevisiae andC. glabrata . The presence and absence of glucose
in C. glabrata leads to similar changes of transcription, as in S.
cerevisiae [50]. To escape the host defense mechanisms, varia-
tions of the yeast morphology can permit the burst from phago-
cytotic cells. Candida glabrata is capable of detoxifying radical
oxidative species and seems to disrupt normal phagosomal mat-
uration, leading to the inhibition of phagolysosome formation
and phagosome acidification [51]. In terms of starvation, C.
glabrata autophagy is used for intracellular nutrient mobiliza-
tion, being vital for its virulence. It is a highly controlled process
and needs a number of factors for the correct recognition, pack-
aging, and delivery of cargo to the vacuole [52–54]. Candida
glabrata survives the defense mechanisms induced by the mac-
rophage, including largely oxidative stress.
Host–pathogen interaction demands numerous crucial func-
tions achieved by proteins of the cell wall, such as tissue
adhesion, invasion and biofilm formation, protection from host
defense mechanisms, triggering of the host immune system,
and resistance to antifungal drugs [55]. Candida glabrata
adherence to the host epithelial tissue is mainly mediated by a
number of glycosylphosphatidylinositol (GPI)-linked adhesin
genes [56, 57], some induced inC. glabrata cells from biofilms
[58]. Its genome (ATCC 2001) covers 67 genes encoding
putative adhesin-like GPI-modified cell wall proteins, including
the Epa family with 17 members [59], and their expression is
regulated. Moreover, C. glabrata cells carrying mutations in
some loci show a rise in adherence to epithelial cells and are
able to colonize organs more efficiently [60–62]. In fact, there
are several factors tangled in the development of C. glabrata
infection. Naturally, these features promote the pathogenicity
performing together and depend on the species characteristics
itself and the host physiology conditions, specifically the state
of its immune system [62].
A model using a reconstituted human oral epithelium
(RHOE) infected only with C. glabrata or simultaneously
with C. glabrata and C. albicans showed that C. glabrata
strains originating from the oral, vaginal, and urinary tract
were able to colonize the tissue but in a strain-dependent
manner. Single infection withC. glabrata showed no invasion
of the RHOE but mixed infection showed that C. albicans
enhanced the invasiveness of C. glabrata [63] (Fig. 1). The
results obtained by these authors demonstrated an enhanced
invasion and increased tissue damage caused by mixed C.
glabrata and C. albicans infections, which has important
clinical significance and highlights the need to better identify
Candida species involved in oral candidosis.
Jayatilake et al. [64] also used an RHOE model to study
host interaction and the virulence factors in oral candidiasis
induced by C. albicans and NCACs, using mutated species.
All C. albicans isolates invaded the tissue over 48 h. The
invasive potential of hyphal and SAP (secreted aspartyl pro-
teinases) mutants was similar to the parent wild-type isolate at
12 h, although after 24 h, their invasion was dissimilar.
NCACs and hyphal mutants were all non-invasive and the
second most pathogenic group comprised C. albicans with C.
glabrata . This study supports the theory that the conversion
from the blastospore phase to the hyphal phase is an important
virulence attribute of C. albicans , in comparison with
NCACs, showing also that, for these species (including C.
glabrata), it is necessary to focus on other features in order to
understand and to contour NCAC species infections. There
are no in vivo studies concerning C. glabrata infection. In
vivo models can give additional information on what is oc-
curring inside the cell, organ, and/or organism.
Virulence factors in Candida glabrata
Decades ago, it was assumed that yeasts passively contributed
to the process of pathogenesis in the establishment of a fungal
infection. Consequently, organic weakness or an immuno-
compromised host was considered the only mechanism re-
sponsible for the establishment of opportunistic infection.
Nowadays, this concept has been modified and it is known
that these organisms dynamically participate in the pathophys-
iology of the disease process using mechanisms of aggression
called virulence factors [2, 65]. Moreover, the pathogenicity
of Candida species is attributed to certain virulence factors,
such as the ability to evade host defenses by filamentous
forms, adherence ability, biofilm formation capacity (on host
tissue and on medical devices), and the production of tissue-
damaging hydrolytic enzymes such as phospholipases, li-
pases, and hemolysins [2, 65].
The fairly non-pathogenic nature of C. glabrata in animal
models suggests that it has few virulence attributes; neverthe-
less, its high mortality rate and rapid dissemination points to
the opposite. However, it is known that C. glabrata possess
several factors tangled in the development of an infection.
Naturally, these features promote the pathogenicity
performing together and depend on the C. glabrata charac-
teristics itself and the host physiology conditions, specifically,
the state of its immune system [65].
Adhesion and biofilm formation
Candida glabrata is capable of colonizing host tissues as well
as abiotic surfaces, where it develops as a multilayered biofilm
structure [66, 67], despite not being able to form filaments. An
important factor correlated with the adhesion ability of
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Candida species is the presence of specific proteins on its cell
wall, namely, adhesins. In C. glabrata , a major group of
adhesins is encoded by the Epa (epithelial adhesin) gene
family [68]. The overall structure of Epa proteins is similar
to that of the Als (agglutinin-like sequence) proteins of C.
albicans . Although there are few studies concerning C.
glabrata Epa proteins, it is known that Epa1p is a Ca2+-
dependent lectin that binds to N-acetyllactosamine-
containing glycoconjugates [69]. Furthermore, despite the
large number of EPA genes, it has been shown that the
deletion of merely EPA1 reduces in vitro adhesion [68].
However, although EPA6 is not expressed in vitro, its expres-
sion increases during in vivo urinary infection, suggesting that
C. glabrata is able to adapt to different environmental condi-
tions [60, 64].
EPA6 and its close paralogue EPA7 are located in
subtelomeric regions and their transcription is regulated by
Sir4p and Rif1p, two proteins involved in subtelomeric silenc-
ing. Biofilm growth conditions induce the transcription of
EPA6 and EPA7 : this is dependent on the presence of an intact
subtelomeric silencing machinery and is independent of the
Mpk1p signaling pathway. Finally, the kinase Yak1p is re-
quired for the expression of both adhesin genes and acts
through a subtelomeric silencing machinery-dependent path-
way [67].
Biofilm forming ability may confer C. glabrata an ecolog-
ical advantage, aiding survival as commensals and pathogens
of humans by allowing them to evade host immune mecha-
nisms, resist antifungal treatment, and withstand the compet-
itive pressure from other microorganisms [70]. Biofilm for-
mation in C. glabrata , besides possibly being a key factor for
the survival of these species, may also be responsible for them
being particularly well adapted to the colonization of tissues
and indwelling medical devices. Comparing with the other
Candida species, C. glabrata displays the lowest biofilm
metabolic activity, despite having the highest number of bio-
film cultivable cells. Likewise, the metabolic activity of re-
suspended C. glabrata biofilm and planktonic cells is lower
than that of the other species [70]. Thus, generally, C.
glabrata biofilms have less total biomass and its strains show
similar biofilm forming ability, in opposition to C.
parapsilosis and C. tropicalis . Candida glabrata biofilms
often display a structure of a multilayer with blastoconidia
intimately packed or constituted by clusters of cells with, in
both cases, total absence of pseudohyphae and hyphae
(Fig. 2). Remarkably, biofilm matrices of C. glabrata have
relatively higher quantities of protein and carbohydrate (in
some cases, five times higher) compared with other NCACs
[2, 64, 70].
Biofilm conditions and high cell density are adhesion in-
ducers, activating EPA6 , whereas EPA1 is triggered typically
in the lag phase [67, 68]. This complex regulation of adhesin
genes in C. glabrata is reminiscent of the greatly and com-
plicated regulation of S. cerevisiae flocculation (FLO ) genes.
Indeed, FLO11 is one of the genes regulated by the Swi/Snf
complex [71, 72]. Thus, reliable with the knowledge that
adhesion of C. glabrata to host epithelial tissue plays an
important role in virulence, the genes FLO1 , FLO5 , and
FLO10 were studied and were found to be Pdr1-dependent
[73]. In C. glabrata , FLO10 (named EPA1 ) is essential for
effective in vitro adherence to human epithelial cells, evidenc-
ing a role for EPA1 in adherence to abiotic materials [69].
FLO5 has been described as a member of the Epa family of
adhesion proteins in C. glabrata ; however, its role in adher-
ence has not been openly studied. The link between FLO and
EPA genes prove that its regulation may control the adherence
of Candida species during the host interactions, conferring
distinct adhesion profiles towards human proteins and cells
[74, 75]. This regulation is variable among species and even
between strains of the same species [75].
Fig. 1 Single (a) and co-
infection (b) ofCandida glabrata
and Candida albicans of a
reconstituted human epithelium
after 12 h, assessed by laser
scanning microscopy. The arrow
indicates C. glabrata cells
invading the epithelium
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A study using isolated mutant strains allowed the identifi-
cation of four genes involved in biofilm formation: silent
information regulator (SIR4 ), telomere-binding (RIF1 ),
EPA6 , and serine-threonine protein kinase, YAK1 [69]. More-
over, like in C. albicans and C. parapsilosis , in C. glabrata ,
the transcription factor Bcr1 is a dominant regulator of the
biofilm development, though the full extent of its regulation
remains unknown [76].
Enzyme production
In the Candida genus, the so-called virulence factors com-
prise not only the adhesion and biofilm formation, but also the
ability to destroy host tissues, which may be facilitated by the
release of hydrolytic enzymes into the local environment. The
general secretion of enzymes, such as proteases, phospholi-
pases, lipases, and hemolysins, help the yeasts to survive and
replicate within macrophages, being able to destroy the epi-
thelium. As mentioned earlier, C. glabrata do not produce
proteases, in opposition to the rest of theCandida species [69,
70]. In fact, there is one study that has shown that this species
is capable of proteinase production, but the type of proteinase
was not specified [77].
Phospholipases (PLs) hydrolyze phospholipids into fatty
acids and their production contribute to host cell membrane
damage, promoting cell damage or exposition of receptors that
facilitate adherence. Candida glabrata produces phospholi-
pases, which clearly promotes a greater and powerful interface
with the host mucosae, destroying it and endorsing an effec-
tive invasion of the tissues involved [78–80].
Lipases are tangled in the hydrolysis of triacylglycerols,
which are also produced by C. glabrata . In C. albicans , ten
genes encoding for lipases have been identified and it has been
shown that mutants were significantly less virulent in a murine
intravenous infection model. Sequences similar toC. albicans
(LIP1-10) were also detected in C. tropicalis , but not in C.
glabrata [78–82].
Newly, some authors described that NCAC species, such as
C. glabrata , have been able to degrade hemoglobin using
hemolysins in order to obtain iron [83, 84]. Like other Can-
dida species, C. glabrata can grow in the host by degrading
hemoglobin and extracting the elemental iron from host cells
for metabolic processes. The assembly of this hemolytic factor
may be regulated by the presence of glucose in the growth
medium. Candida glabrata and other NCAC species are able
to produce hemolysins in vitro, bringing partial or total eryth-
rocyte lyses, though the extent of this is both strain- and
species-dependent [85, 86]. Although hemolysins are known
to be putative virulence factors backing pathogenicity in Can-
dida species, the genetic expression of hemolytic activity in
C. glabrata is poorly understood. Luo et al. [85] revealed that
a hemolysin-like protein (HLP) gene was allied with the
hemolytic activity of C. glabrata .
Drug resistance mechanisms in Candida glabrata
Antifungal drug mechanisms
As already remarked, there are many antifungal classes, which
have different mechanisms of fungicidal or fungistatic action
on Candida species. Azoles, like fluconazole, itraconazole,
ketoconazole, miconazole, voriconazole, posaconazole, and
rosaconazole, are able to block the ergosterol biosynthesis
by the inhibition of lanosterol 14α-demethylase, leading to a
diminished ergosterol production. Moreover, they are respon-
sible for the lack of ability to build and renew sterols in the
cellular membranes, changing the membrane fluidity and
function of vital processes such as signaling, transport, exo-
cytosis, and endocytosis. Polyenes, such as amphotericin B,
nystatin, and pimaricin, link to the ergosterol molecules,
resulting in pores on the cell wall and, thus, increasing cell
permeability. Antimetabolite antifungal drugs, such as 5-
fluorocytosine, inhibit RNA function and, finally, the
allylamines and a chitin synthase inhibitor, the nikkomycin
Z. Figure 3 summarizes the mechanisms of antifungal action.
Each antifungal class uses distinct means to eradicate or
inhibit the growth of fungal pathogens. The mechanisms of
antifungal resistance are categorized as primary or secondary
and are related to intrinsic or acquired characteristics of the
fungal pathogen, including interference with the antifungal
Fig. 2 Candida glabrata
American Type Culture
Collection (ATCC) 2001 48-h
biofilm formation in Sabouraud
Dextrose Broth (SDB).
Magnification 1,000× (left) and
3,000× (right)
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mechanism of the respective drug or the decrease in target
drug levels [15].
Genomic plasticity is an important machinery for adapta-
tion to environmental signs, such as host responses and anti-
fungal drug pressure in many fungi, including C. glabrata .
For example, the C. glabrata genome has lost genes involved
in galactose and sucrose assimilation, phosphate, nitrogen,
and sulfur metabolism, as well as thiamine, pyridoxine, and
nicotinic acid biosynthesis [12, 15].
In 2012, Bader et al. [87] analyzed the derivatives in C.
glabrata strains’ genomes. These were shown to be indistin-
guishable by multilocus sequence typing, but dissimilar phe-
notypic groups that correlated with specific karyotypic chang-
es were also detected. Alterations that can significantly affect
phenotypic properties, for example, in the quantitative chang-
es in adhesin genes expression and the cell wall carbohydrate
composition, could also be noticed rather than subtelomeric
genes loss or differences in the number of macrosatellite
repeats within adhesin genes. It is important to highlight that
these phenomena, such as chromosomal aberrations and func-
tional adaptations, may occur during infection and under
antimicrobial therapy, but also under laboratory conditions
deprived of extreme selective pressures. Rai et al. [88] showed
that chromatin alterations could happen as essential strategies
of survival, which facilitates a reprogramming of cellular
energy metabolism in macrophage-internalized C. glabrata
cells, and provide protection against DNA damage.
So, C. glabrata , like all Candida species, possess the
ability to answer to the environmental alterations aimed to
adapt to the presence of antifungal agents and, in this way,
provide protection against antimicrobial therapies [62].
Antifungal resistance is both complex and multifaceted. It
can be inducible in response to a compound or be an irrevers-
ible genetic change resulting from prolonged exposure. In
detail, these include alterations or even an overexpression of
target molecules, active extrusion through efflux pumps,
limited diffusion, tolerance, and cell density, which are all
characterized mechanisms utilized by fungi to combat the
effects of antifungal treatments [89]. Planktonic cells general-
ly rely on irreversible genetic changes to maintain a resistant
phenotype, whereas biofilm cells are able to persist due to
their physical presence and the density of the population,
which provides an almost inducible resistant phenotype irre-
spective of defined genetic alterations. Thus, C. glabrata has
an intrinsically reduced susceptibility to commonly used
antifungal drugs due to different properties, which are
summarized in Table 2.
Active efflux from procaryotic as well as eucaryotic cells
strongly modulates the activity of a large number of antifun-
gals. Inside the group of primary active transporters, predom-
inant in eucaryotes, six families belonging to the ATP-binding
cassette superfamily, and including the P-glycoprotein in the
MDR (multidrug resistance) group and the MRP (multidrug
resistance protein), have been recognized as being responsible
for antibiotic efflux [90, 91]. Within the class of secondary
active transporters (antiports, symports, and uniports), ten
families of antibiotic efflux pumps have been described and
distributed in five superfamilies [SMR (small multidrug resis-
tance), MET (multidrug endosomal transporter), MAR
(multiantimicrobial resistance), RND (resistance nodulation
division), andMFS (major facilitator superfamily)]. In eucary-
otes, antibiotic efflux pumps modulate the accumulation of
antimicrobials in phagocytic cells and play major roles in their
transepithelial transport [91].
Table 3 summarizes the genes discussed above and others
that are involved in C. glabrata resistance to antifungal drugs.
Azoles and resistance
Candida glabrata grows only as a yeast form in vivo and its
adhesion is relatively weak [91–93], so it is believed that the
increase ofC. glabrata infections is due to its intrinsically low
Fig. 3 Mechanisms of action of
antifungal drugs
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susceptibility to azoles, including the imidazoles (e.g., micon-
azole) and the oral-parenteral triazoles (e.g., fluconazole,
voriconazole) [94]. The development ofC. glabrata infections
parallels the introduction, in the early 1990s, of triazoles and
over-the-counter imidazoles. Acquired resistance results from
rare mutations that are selected by drug pressure [95]. All the
genes involved in the biosynthesis of ergosterol are expected to
be upregulated in case of the presence of azole molecules.
Nevertheless, ERG genes are the ones more focused on in
studies. Between them are ERG1 , ERG3 , ERG6 , ERG7 ,
ERG9 , and especially ERG11 . ERG11 is involved in the
reaction that converts lanosterol into 4,4-dimethylcolesta-8,
14,24-trienol. This gene is noticeably more referred as the
central point on the increase of ergosterol production, in re-
sponse to the azole attack to the Candida cell membrane,
especially inC. glabrata , which has great ease to acquire azole
resistance [90, 95]. Potential mechanisms to azole resistance
include a small affinity of its lanosterol 14α-demethylase or a
high ability to upregulate ERG11 (ergosterol biosynthesis
genes), CDR1 , and PDR1 expression following azole expo-
sure [48]. Acquired resistance results from rare mutations that
are selected by drug pressure [95–97]. Mitochondrial dysfunc-
tion is another of the possible mechanisms by which azole
resistance can occur in C. glabrata . Moreover, the develop-
ment of the “petite mutants” (cells with mitochondrial DNA
deficiency) upregulates the ATP-binding cassette (ABC) trans-
porter genes, exposes amplified resistance to azoles, and en-
dears a drastic improvement of fitness. However. there is a lack
of information about the real involvement of the “petite mu-
tants” in azoles’ Candida resistance [98]. However, by screen-
ing a library of 9,216 random insertion mutants, Kaur and
colleagues [99] identified a set of 27 genes, which, upon
mutation, confer changed fluconazole susceptibility in C.
glabrata . These genes comprise those belonging to the family
of ABC transporters (PDR5 and PDR16), genes involved in
retrograde signaling from mitochondria to nucleus (RTG2),
and genes involved in diverse cellular functions (activation of
RNA polymerase II transcription, calcium homeostasis, ribo-
somal biogenesis and mitochondrial function, nuclear ubiqui-
tin ligase function, and cell wall biosynthesis). Those authors
studied two kinds of mutants, the first being the Cch1-Mid1,
defective in calcium uptake in response to fluconazole expo-
sure, in which they noticed that the strains flawed in a putative
plasma membrane calcium channel were discreetly more sus-
ceptible to fluconazole but revealed a significant loss of via-
bility upon prolonged fluconazole exposure, proposing that
calcium signaling is necessary for the survival of azole stress
Table 2 Summary of the most relevant factors involved in Candida glabrata antifungal resistance
Factor Description References
Tolerance Pathogenic fungi encounter and bear a range of physiological stresses from
different environments: temperature changes, ionic stress, changes in
osmolarity, and oxidative stress (e.g., phagosomes of neutrophils)
[118]
Environmental stress pH, temperature, oxygen availability, etc. [119, 121–125]
Cell density Mature biofilms, whilst densely populated, exhibit spatial heterogeneity [119, 126, 127]
Efflux pump-mediated resistance Exocitosis of the drug [128–134]
Extracellular matrix Presence of extracellular matrix, which is an essential characteristic of
fungal biofilms, providing the cells with protection from hostile factors
[21, 34, 135]
Genetic alterations Like overexpression of genes related with drug targets [135–141]
Persister cells These are “dormant variants of regular cells that form stochastically in microbial
populations and are highly tolerant to antibiotics”. They are a vital mechanism
of resistance in chronic infections
[24, 142–144]
Table 3 Genes of Candida glabrata involved in resistance to antifungal
drugs
Gene Function References
EPA family Adhesion [67–69]
SIR3 , RIF1 [69]
ERG family Ergosterol biosynthesis [101]
PDR1 ABC transporters [102]
CDR1–4 , SNQ2 [101–103]
BCR1 Biofilm formation [104]
FKS1–2 β-1,3 glucan biosynthesis [61, 101,
105–108]
YPS family Adhesion
Colonization
[109]
CTA1 Oxidative stress processes [43, 110]
ATG11 , ATG17 Phagocytosis survival [43]
MDR1 and FLR1 Major facilitator family; MFS
transporters
[101]
Kre1 and SKN1 β-1,6 glucan biosynthesis [101]
ACE2 General virulence [111–114]
ARO Pigmentation
Oxidative stress processes
[115]
ZAP1, GCAL1,
ADH5, CSH1
Extracellular matrix regulators [101]
Afu MDR4 ABC transporters [101]
MCK1 MAPK [101]
HSP90 Heat shock processes [101]
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in C. glabrata . Thus, in the absence of Ca2+ signaling, flucon-
azole has a fungicidal rather than a fungistatic effect on C.
glabrata . Finally, in the second set of mutants, defective in
mitochondrial assembly and organization, the cells exhibited
very high levels of fluconazole resistance, indicating an exis-
tence of a mechanism for the reversible loss of mitochondrial
function that does not involve loss of the mitochondrial ge-
nome and that C. glabrata can shift between states of mito-
chondrial competence and incompetence in response to flu-
conazole exposure [100]. Candida glabrata calcineurin mu-
tants exhibit increased susceptibility to both azoles and cell
wall-damaging agents and are also attenuated in virulence.
While a mutant lacking the transcription factor Crz1, a
calcineurin-regulated transcription factor, displayed a cell
wall-associated phenotype intermediate to that of the calcine-
urin mutant and was modestly attenuated in virulence, it did
not show amplified azole susceptibility, suggesting that cal-
cineurin regulates both Crz1-dependent and -independent
pathways, depending on the type of stress [100].
Candida glabrata has intrinsic azole resistance or ac-
quires, very easily, drug resistance during prolonged azole
therapy, by undergoing mutation either in vitro or in vivo
[101]. Several ABC transporters, including Cdr1p, Pdh1p
(also known as CDR2 ), Yor1p, and Snq2p, contribute to
xenobiotic drug efflux. The transcription factor Pdr1p is the
principal regulator of ABC transporter gene expression and
has been found to be a key component of pleiotropic drug
resistance (PDR ) [102, 103]. A C. glabrata open reading
frame (CAGL0I02552g) codes for a protein conserved
among hemiascomycete binuclear zinc cluster proteins,
showing a common ancestry and, probably, an important
function in these yeasts. Pdr1p has been found to form a
heterodimer with Stb5p in S. cerevisiae . Transcriptional
analysis signposted a shared regulon among the homo-
logues of these two genes, PDR1 and STB5 , in C. glabrata ,
and many of the genes upregulated by the overexpression of
PDR1 were upregulated by the deletion of STB5 . Thus, the
PDR1 overexpression and STB5 deletion are correlated
[104, 105]. The overexpression of STB5 in C. glabrata
represses azole resistance, while the deletion of STB5 pro-
duces a shy intensification in resistance. Expression analy-
sis assays established that STB5 shares many transcription-
al targets with PDR1 but, unlike the second, it is a negative
regulator of pleiotropic drug resistance (including the ABC
transporter genes CDR1 , PDH1 , and YOR1 ) [105, 106].
Transcript profiling with microarrays showed that more
than 385 genes are differentially regulated by a selected num-
ber of the gain-of-function (GOF) mutations expressed in the
same genetic background, with a minimal overlap in co-
regulated genes. CDR1 and PUP1 (for PDR1 upregulated
and encoding a mitochondrial protein) were generally upreg-
ulated by all tested GOFs. While both genes mediated azole
resistance (with in vitro and in vivo expression, though to
different extents), their deletions in an azole-resistant isolate
managed a decline in virulence and a decrease in tissue load.
Their individual overexpression was showed to partially re-
store phenotypes obtained in clinical isolates [106].
AP1 ortholog encodes a transcription factor involved in
various stress responses. Chen et al. [107] showed that AP1
plays a critical role in the reaction to various stresses in C.
glabrata and reduces the stress through transcriptional acti-
vation of its target genes, including FLR1 . They demonstrated
that the deletion of FLR1 in C. glabrata only resulted in
increased sensitivity to benomyl, diamide, and menadione,
but not 4-NQO, cycloheximide, or fluconazole.
The aldo-keto reductase superfamily is known to be upreg-
ulated in the resistant C. glabrata clinical isolates. Reverse
transcription quantitative polymerase chain reaction (RT-
qPCR) reveals AKR mRNA expression about twice that seen
in the sensitive isolates. Thus, this overexpression of the AKR
gene is associated with amplified fluconazole and itraconazole
resistance, suggesting that upregulation of the AKR gene
might give a new insight into the mechanism of azole resis-
tance [61, 108].
Echinocandins and resistance
Echinocandins are front-line agents against invasive candidi-
asis (IC), but conjectures for echinocandin therapeutic failure
are arising; however, they are not well demarcated. This class
of antifungal agents is considered to be the first-line treatment
of IC due to C. glabrata , but this NCAC species has already
been described as developing reduced susceptibility to
caspofungin during prolonged therapy. Studies involving
sequentiation of hot spots, known to confer echinocandin
resistance, revealed an F659V substitution within the FKS2
region of the glucan synthase complex [109].
Recently, strains of C. glabrata have also been detected to
be resistant to both fluconazole and the echinocandins. In
these strains, an acquired mutation in FKS1 or FKS2 was
detected [110]. These mutations in Candida FKS genes,
which encode the enzyme targeted by echinocandins, end in
elevated minimum inhibitory concentration (MIC) and have
been linked to therapeutic failures. Micafungin MICs of C.
glabrata FKS hot spot mutant isolates were perceived to be
less elevated than those obtained for the other echinocandins,
showing that the efficacy of micafungin could be differentially
dependent on specific FKS genes mutations [111]. Interest-
ingly, in another study, echinocandin MICs and FKS1 and
FKS2 mutations among C. glabrata isolates were correlated
with echinocandin therapeutic responses.FKS mutations were
detected and the median caspofungin and anidulafunginMICs
were higher for patients who failed therapy [112]. In another
study [113] from patients with C. glabrata bloodstream in-
fections at Duke University Hospital in Durham, NC, the
treatment outcome (using anidulafungin, caspofungin, and
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micafungin) was correlated with the MIC results and the
presence of FKS1 and FKS2 gene mutations. The results
showed that the resistance to echinocandins increased from
4.9 to 12.3 % between 2001 and 2010. Moreover, among the
78 fluconazole-resistant isolates, 14.1 % were resistant to one
or more echinocandins. Almost 8 % of the isolates had an
FKS mutation, which appeared due to a prior echinocandin
therapy, and virtually all of them demonstrated intermediate or
resistant MICs to an echinocandin (failure or recurrence of
infection). Additionally, the new Clinical and Laboratory
Standards Institute (CLSI) clinical breakpoints differentiate
wild-type from C. glabrata strains bearing clinically signifi-
cant FKS1 /FKS2 mutations.
Polyenes and resistance
The molecular mechanisms that lead to polyene resistance are
still poorly documented, especially in C. glabrata strains. In a
previous study [114], a clinical isolate of C. glabrata showed
lower ergosterol content in its membrane than the wild-type,
and this low content was established to be linked to a nonsense
mutation in the ERG6 gene and to the induction of the
ergosterol biosynthesis pathway. Variations of the cell wall
were also perceived, accompanied by improved susceptibility
to cell wall-perturbing agents, with a high rate of cell mortal-
ity. In conclusion, the nonsense mutation detected in the
ERG6 gene of this isolate led to a decrease in ergos-
terol content [114].
Moreover, an other clinical isolate of C. glabrata with a
poor susceptibility to polyenes and recovered from a patient
treated with amphotericin B was analyzed by Vandeputte et al.
[115], demonstrating that a mutation in the ERG6 gene leads
to a reduced susceptibility to polyenes and to subsequent
changes in the sterol content of the plasma membrane. Thus,
a deficiency of ergosterol and an accumulation of late sterol
intermediates was shown, highlighting a defect in the final
steps of the ergosterol pathway. Sequencing exposed a unique
missense mutation in ERG6 , leading to the substitution of a
cysteine by a phenylalanine in the corresponding protein.
Later, a real-time PCR proved an overexpression of the genes
that encode enzymes involved in late steps of the ergosterol
pathway. The complementation of this strain with a wild-type
copy of the ERG6 gene reestablished susceptibility to poly-
enes and a classical morphology [115].
Other antifungal agents’ resistance
Allylamines: A study developed by Vermitsky and Edlind
[103] showed that the treatment with terbinafine, which tar-
gets the enzyme squalene epoxidase in the ergosterol biosyn-
thetic pathway, found upregulation on ERG11 as previously
reported but, unlike in the azoles case, had a minimal effect on
CDR1 and PDH1 .
Histatin 5: In order to develop new antimycotics with
possibly diverse cellular targets, histatins, a group of human
salivary cationic proteins, were studied [116–120]. Histatins
are extremely effective against diverse classes of fungi, but
they are significantly less effective against C. glabrata , being
hypothesized that C. glabrata might escape histatin 5 activity
by applying fermentative pathways, since, theoretically, glu-
cose can either be fermented or assimilated. Furthermore, C.
glabrata is a Crabtree-positive fungus [121], and its respira-
tion could be negatively affected by certain levels of glucose
[122]. The results confirm an apparently fundamental and
extensive resistance of C. glabrata to histatin 5, though
the resistance to histatin 5 is not related to the resistant
mechanisms of azoles.
Pathogenic fungi represent a special problem in the clinic,
as the range of drugs that can be used to treat these kinds of
infections is restricted. This situation is further complicated by
the presence of robust inducible gene networks encoding
different proteins that confer tolerance to many available
antifungal drugs [123]. Moreover, it is important to state that
C. glabrata has frequently been reported as exhibiting vari-
able karyotypes between isolates [124–131] and several
works have shown that these karyotypes are rather stable,
hypothesizing that the karyotype of virulent species is more
stable than avirulent species [132]. The major karyotypic
differences between C. glabrata strains are related to a small
number of chromosomal translocations. Along with variation
in the subtelomeric EPA genes, the other genomic rearrange-
ments are copy number variations in tandem gene repeats,
encoding putative or known cell wall proteins [125].
The role of biofilms in Candida glabrata resistance
As already seen, most microorganisms exist in nature as
complex communities, the biofilms, which are attached to
surfaces rather than isolated free-floating planktonic organ-
isms. These structurally and functionally complex communi-
ties consist of one or more microbial species encased in an
extracellular polymeric substance, and attached to one another
or to a solid surface [132]. A broad variety of environmental
factors contribute to the initial surface attachment of Candida
cells: pH, temperature, osmolarity, presence of bacteria, the
flow of the surrounding medium (urine, blood, saliva, and
mucus), presence of antimicrobial agents, and host immune
factors [133–137]. Fungal biofilms are formed in different
phases of development, including arriving at an appropriate
substratum, adhesion, colonization, extracellular matrix
production, biofilm maturation, and dispersal [125,
134, 138–140].
Comparing planktonic cells to biofilms, the latter are much
more resistant to antimicrobials, and are thought to be in-
volved in up to 65 % of all human microbial infections
[141]. It has recently been proved that the cells that detach
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from the biofilm have a greater association with mortality than
equivalent planktonic yeasts [142]. As yet, there appears not
to be one specific resistance factor responsible for the in-
creased recalcitrance to antifungal agents exhibited by
biofilms. Instead, biofilm resistance is a complex multifacto-
rial phenomenon, which still remains to be fully elucidated
and understood. Different mechanisms may be responsible for
the intrinsic resistance ofCandida biofilms and specificallyC.
glabrata . These include the following: (i) high density of cells
within the biofilm; (ii) effects of the biofilm matrix; (iii)
decreased growth rate and nutrient limitation; (iv) expression
of resistance genes, particularly those encoding efflux pumps;
and (v) presence of “persister” cells.
The cell density is an important factor for antifungal resis-
tance in biofilms, particularly for azoles. One study showed
that both planktonic and biofilm cells exhibit sensitivity to
azoles with low numbers of cells (103 cells/mL), becoming
increasingly resistant with an improved density. In dense
biofilms, there is a cooperation between cells through process-
es named “quorum sensing”, enabling organizations to com-
municate and coordinate their behavior by the secretion of
signaling molecules, which are dependent on the population
density [143, 144].
Regarding the biofilm matrix, one supposition is that the
existence of the matrix reduces the penetration of drugs
through the establishment of a diffusion barrier, as an ion-
exchange resin, binding charged antibiotic molecules [24],
like antifungals. Moreover, it is known that planktonic cells
generally rely on irreversible genetic changes to maintain a
resistant phenotype, whereas biofilms are able to persist due to
their physical presence and the density of the population,
which provides an almost inducible resistant phenotype irre-
spective of defined genetic alterations [144]. Candida
albicans experiments with resuspended sessile cells recovered
from mature biofilms indicated that, when tested as free-
floating cells, they were also resistant to fluconazole and
amphotericin B challenge, but not to the same level as that
found in the mature biofilms from which they were derived.
Moreover, in mixed biofilms, the extracellular matrix pro-
duced by bacterial cells was shown to retard the diffusion of
the antifungal agents, but poor penetration did not account for
the drug resistance of Candida biofilm cells. Overall, these
results seem to indicate that, although the extracellular matrix
plays a partial role in sessile resistance, the influence of other
factors is also significant [144].
In fact, the ability to form biofilms is intimately associated
with the ability to cause infection and, so, it should be con-
sidered an important virulence determinant during candidosis.
The biofilm lifestyle results in antifungal drug resistance and
protection from host defenses, both of which carry important
clinical repercussions. Molecular studies on biofilm formation
have begun to shed light on the driving forces behind the
transition to the biofilm mode of existence, which, in the
future, may offer a potential therapeutic avenue. The applica-
tion of powerful DNAmicroarray and proteomic technologies
should facilitate a more detailed analysis of the biofilm life-
style [145, 146].
Some biofilm formation genes are beginning to be brought
up by researchers concerning different roles in this process.
Between them, we can find the peroxisomal catalase (CTA1),
the biosynthesis and degradation of tyrosine genes (ARO), the
muscle creatine kinase (MSK ), the heat shock protein 90
(HSP90 ), the sphingolipid biosynthesis (SKN1 and KRE1),
SIR , RIF, and, finally, the extracellular matrix regulators:
zinc-regulated genes (ZAP1 ), g-carbonic anhydrase
(GCAL1), alcohol dehydrogenase (ADH5 ), and also cell sur-
face hydrophobicity (CSH1 ) [144, 145].
The immunoevasion and intracellular persistence of C.
glabrata may be a key factor in the capability of this species
to persist in the course of multiple antifungal treatments and
develop multidrug resistance. Second, changes in the cell wall
associated with antifungal resistance often favor evasion for
the host immune response [67, 72].
Lastly, extracellular polysaccharides are crucial elements of
the biofilm matrix of many microorganisms. β-1,3 glucan, a
very important polysaccharide in yeast, has been associated to
biofilm protection from antifungal agents. The authors [147]
identified three glucan modification enzymes that deliver
glucan from the cell to the extracellular matrix, playing a
biofilm-specific role, by mediating the delivery and organiza-
tion of mature biofilm matrix. The enzymes consist of two
glucan transferases and an exoglucanase, encoded by BGL2 ,
PHR1 , and XOG1 , respectively. The enzymes did not appear
to affect the cell wall glucan composition of biofilm cells, nor
are they necessary for filamentation or biofilm formation.
Later, they also revealed that mutants missing these genes
exhibit higher susceptibility to fluconazole during biofilm
growth only. Transcriptional analysis and biofilm phenotypes
of strains with multiple mutations propose that these enzymes
allocate matrix downstream of the primary β-1,3 glucan syn-
thase encoded by FKS1 [147].
The responses of organisms to stress have been recognized
as antifungal resistance mechanisms of biofilms. Fungi are
faced with different types of physiological stress from the
surrounding environment, including changes in temperature
or nutrients, ionic stress, changes in osmolality, and oxidative
stress. These receptors are detected by a number of cells which
induce responses by signaling pathways [148]. A study with
C. glabrata showed that there is a positive regulatory protein
of the stress response in biofilms of this kind, shown in the
heat shock proteins (Hsp12p) and other stress proteins (Trx1
and Pep4) [149]. Persister cells are an important mechanism of
resistance in chronic infections [144], which has received
some attention in fungal biofilms. They are variants dormant
in normal cells formed occasionally in microbial populations
which are highly tolerant to antimicrobial agents. The first
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study of persister cells in Candida was performed with C.
albicans , where such cells were detected only in biofilms. In
this study, re-inoculation of cells that survived the destruction
of biofilms with amphotericin B produced a new biofilm with
a new subpopulation of persister cells, suggesting that these
cells were not mutants but wild-type phenotypic variants and
that the binding to a substrate initiated the dormancy state.
Subsequently, a study with isolated persister cells of C.
glabrata demonstrated that prolonged and ineffective antifun-
gal therapy may be beneficial for the biofilm and its effect may
be responsible for the failure and recurrence of fungal infec-
tions [150–153].
Main research to develop regarding Candida glabrata
Unfortunately, there are still several issues to explore regard-
ing the course of infection by C. glabrata . Among them, we
highlight the following avenues:
– Definition of the true role of FLO genes, which can bring
useful answers regarding the adhesion process during the
biofilm production;
– Introduction of the in vivo studies. The in vivo cells
contain several types of machinery and molecules that
can be helpful to the experiment. The in vivo approach
could also be important to the evolution of host-
interaction research and the definition of new tactics
regarding the strategies of remission of the C. glabrata
pathologies;
– Revisions on the topic of the genes involved directly on
the biofilm formation. Their role is still not well elucidat-
ed and could yield the key to blocking biofilm growth;
– Explanation of the real part of the biofilm in C. glabrata
in the antifungal resistance process (and the other species
of the genus). Characterization of the existent molecules
and their function in the therapeutics and the clinical
approach;
– Future studies should also focus on C. glabrata biofilms’
matrices composition in the presence and absence of
antifungal agents and, thus, investigate the use of new
alternative therapies to reduce and/or eradicate biofilms.
Conclusion
Fluctuations in the host are generally required for the oppor-
tunistic yeasts to modify from harmless commensal microor-
ganisms to potentially life-threatening human pathogens. The
management of candidosis comprises the identification and
control of host factors that may predispose one to infection.
Candida glabrata displays several virulence factors
(adherence, biofilm formation, and secretion of hydrolytic
enzymes), swelling their persistence within the host, trigger-
ing host cell damage, and, finally, resulting in clinical and
microbiological failure. Therefore, the increase in the inci-
dence and antifungal resistance of C. glabrata leads to high
morbidity and mortality, and make it crucial to further develop
our knowledge on the virulence and resistance mechanisms
associated with this species. As long as the various classes of
antifungals are being used, therapeutic or prophylactically,
and sometimes indiscriminately, resistance mechanisms are
emerging, and the therapeutic solutions becoming narrower.
These mechanisms cover all antifungal classes, but mostly the
azoles, which are the most commonly used by physicians, in
both ambulatory and hospital environments.
An improved understanding of the pharmacological toler-
ance phenomena, towards the biochemical mutations and the
pharmacokinetics and pharmacodynamics modifications, can
contribute actively to the identification of new targets for
novel therapeutics against C. glabrata .
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